Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 15

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 8
Chunk 15
---
 uncertainties, we are unable to determine
with any degree of certainty the duration and completion costs of our research and development projects, or if, when, or to what extent
we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may
never succeed in achieving regulatory approval for any of our product candidates.

General
and Administrative Expenses

General
and administrative expenses include compensation, employee benefits, and stock-based compensation, finance administration and human resources,
facility costs (including rent), professional service fees, and other general overhead costs to support our operations.

We
expect our general and administrative expenses to increase for the foreseeable future as we continue to increase our headcount to support
our research and development activities and operations generally, the growth of our business and, if any of our product candidates receive
marketing approval, commercialization activities. We also expect to continue to incur expenses as a result of operating as
a public company, including expenses related to compliance with the rules and regulations of the SEC, additional director and officer
insurance expenses, investor relations activities, and other administrative and professional services.

Other
Income, Net

Other
income, net, includes interest earned on deposits and investments and other items of income, expense, gain and loss that are incidental
to the core operations of the Company.

Results
of Operations

Three
months ended March 31, 2025 compared to three months ended March 31, 2024

The
following table sets forth our results of operations for the three months ended March 31, 2025 and 2024 and the relative dollar change
between the two periods.

    Three months ended  

    March
    31,  
    Change 

    2025  
    2024  
    $  
    % 
  
    Operating expenses: 

    Research and development 
    $2,810,840  
    $1,591,142  
    $1,219,698  
     76.7%
  
    General and administrative 
     1,761,719  
     2,352,097  
     (590,378) 
     (25.1)%

    Total operating expenses 
     4,572,559  
     3,943,239  
     629,320  
     16.0%

    Loss from operations 
     (4,572,559)